Small molecules modulation of 14-3-3 protein-protein interactions.

14-3-3 is a family of highly conserved regulatory proteins which is attracting a significant interest due to its potential role as target for pharmacological intervention against cancer and neurodegenerative disorders. Although modulating protein-protein interactions (PPI) is still conceived as a challenging task in drug discovery, in past few years peptide inhibitors and small molecular modulators of 14-3-3 PPI have been described. Here we examine structural and biological features of 14-3-3 and propose an overview on techniques used for discovering small molecular inhibitors and stabilizers of 14-3-3 PPI.

[1]  C. Ottmann,et al.  A structural rationale for selective stabilization of anti-tumor interactions of 14-3-3 proteins by cotylenin A. , 2009, Journal of molecular biology.

[2]  C. Ottmann,et al.  An optimised small-molecule stabiliser of the 14-3-3-PMA2 protein-protein interaction. , 2012, Chemistry.

[3]  M. Yaffe,et al.  Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. , 2006, Seminars in cancer biology.

[4]  Nikolai N Sluchanko,et al.  Probable participation of 14-3-3 in tau protein oligomerization and aggregation. , 2011, Journal of Alzheimer's disease : JAD.

[5]  S. Masters,et al.  14-3-3 Proteins Mediate an Essential Anti-apoptotic Signal* , 2001, The Journal of Biological Chemistry.

[6]  Yang Liu,et al.  The expression of seven 14-3-3 isoforms in human meningioma , 2010, Brain Research.

[7]  M. Takeda,et al.  Phosphorylation of tau at Ser214 mediates its interaction with 14‐3‐3 protein: implications for the mechanism of tau aggregation , 2009, Journal of neurochemistry.

[8]  A. Fukamizu,et al.  Regulation of FoxO transcription factors by acetylation and protein-protein interactions. , 2011, Biochimica et biophysica acta.

[9]  C. Ottmann,et al.  Impaired Binding of 14-3-3 to C-RAF in Noonan Syndrome Suggests New Approaches in Diseases with Increased Ras Signaling , 2010, Molecular and Cellular Biology.

[10]  P. Assumpção,et al.  Clinical implication of 14-3-3 epsilon expression in gastric cancer. , 2012, World journal of gastroenterology.

[11]  J Günter Grossmann,et al.  Structural basis for protein–protein interactions in the 14-3-3 protein family , 2006, Proceedings of the National Academy of Sciences.

[12]  Xiaoming Li,et al.  14-3-3ζ Overexpression and abnormal β-catenin expression are associated with poor differentiation and progression in stage I non-small cell lung cancer , 2010, Clinical and Experimental Medicine.

[13]  I. Hamachi,et al.  Phosphopeptide-dependent labeling of 14-3-3 ζ proteins by fusicoccin-based fluorescent probes. , 2012, Angewandte Chemie.

[14]  R. Ralhan,et al.  14-3-3 zeta as novel molecular target for cancer therapy , 2012, Expert opinion on therapeutic targets.

[15]  Fabrizio Manetti,et al.  Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3σ case. , 2011, Bioorganic & medicinal chemistry letters.

[16]  S. Yao,et al.  Microarray-assisted high-throughput identification of a cell-permeable small-molecule binder of 14-3-3 proteins. , 2010, Angewandte Chemie.

[17]  Long Yu,et al.  Functional identification of a novel 14-3-3 epsilon splicing variant suggests dimerization is not necessary for 14-3-3 epsilon to inhibit UV-induced apoptosis. , 2010, Biochemical and biophysical research communications.

[18]  C. Ottmann,et al.  Structural insights of the MLF1/14‐3‐3 interaction , 2012, The FEBS journal.

[19]  C. Ottmann,et al.  Phosphorylation‐independent interaction between 14‐3‐3 and exoenzyme S: from structure to pathogenesis , 2007, The EMBO journal.

[20]  Fabrizio Manetti,et al.  Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. , 2010, Bioorganic & medicinal chemistry letters.

[21]  B. Gabrielli,et al.  Phosphorylation of Cdc25B3 Ser169 regulates 14-3-3 binding to Ser151 and Cdc25B activity , 2011, Cell cycle.

[22]  Dihua Yu,et al.  14-3-3ζ as a prognostic marker and therapeutic target for cancer , 2010, Expert opinion on therapeutic targets.

[23]  R. Liddington,et al.  Raf-1 Kinase and Exoenzyme S Interact with 14-3-3ζ through a Common Site Involving Lysine 49* , 1997, The Journal of Biological Chemistry.

[24]  W. Zhang,et al.  Targeting 14-3-3zeta in cancer therapy , 2011, Cancer Gene Therapy.

[25]  C. Ottmann,et al.  Identification and structure of small-molecule stabilizers of 14-3-3 protein-protein interactions. , 2010, Angewandte Chemie.

[26]  Fabrizio Manetti,et al.  Molecular Dynamics and DFT Study on HIV-1 Nucleocapsid Protein-7 in Complex with Viral Genome , 2010, J. Chem. Inf. Model..

[27]  M. Federico,et al.  Identification of protein clusters predictive of response to chemotherapy in breast cancer patients. , 2009, Journal of proteome research.

[28]  Christian Ottmann,et al.  Structure of the p53 C‐terminus bound to 14‐3‐3: Implications for stabilization of the p53 tetramer , 2010, FEBS letters.

[29]  Martin Würtele,et al.  Structural view of a fungal toxin acting on a 14‐3‐3 regulatory complex , 2003, The EMBO journal.

[30]  K. Satoh,et al.  High sensitivity of an ELISA kit for detection of the gamma-isoform of 14-3-3 proteins: usefulness in laboratory diagnosis of human prion disease , 2011, BMC neurology.

[31]  F. Khuri,et al.  Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor , 2011, Proceedings of the National Academy of Sciences.

[32]  M. Botta,et al.  A New Nonpeptidic Inhibitor of 14-3-3 Induces Apoptotic Cell Death in Chronic Myeloid Leukemia Sensitive or Resistant to Imatinib , 2011, Journal of Pharmacology and Experimental Therapeutics.

[33]  A. Stenzinger,et al.  PTPIP51, a positive modulator of the MAPK/Erk pathway, is upregulated in glioblastoma and interacts with 14-3-3β and PTP1B in situ. , 2011, Histology and histopathology.

[34]  Jie Xu,et al.  Aberrant upregulation of 14-3-3ơ expression serves as an inferior prognostic biomarker for gastric cancer , 2011, BMC Cancer.